Lexaria receives AUD$3.67M Australian R&D tax credit for GLP-1 clinical study

Lexaria Bioscience Corp.

Received AUD$3,666,611.98 (USD$2.6M) R&D tax credit from Australian Tax Office on Aug 28, 2026.
Credit relates to clinical study GLP-1-H24-4 conducted by Lexaria (AU) Pty Ltd, wholly-owned subsidiary.
Funds deposited in Australian bank account to pursue additional R&D opportunities in Australia.
Subsidiary holds exclusive DehydraTECH rights for pharmaceutical GLP-1/GIP and CBD drugs in Australia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.